A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Sponsor: |
Eicos Sciences, Inc. |
Enrolling: |
Male and Female Patients |
Study Length: |
35 Days |
Clinic Visits: |
7 |
IRB Number: |
AAAS5867 |
U.S. Govt. ID: |
NCT04040322 |
Contact: |
Biiftu Duresso: 212-342-6815 / bjd2134@cumc.columbia.edu |
The purpose of this study is to find out whether a drug called iloprost is safe to use in people with systemic sclerosis (SSc) (Raynaud's phenomenon), and whether it may help decrease symptomatic digital ischemic episodes (episodes in the fingers).
This study is closed
Investigator
Elana Bernstein, MD
Have you been diagnosed with systemic sclerosis (scleroderma)? |
Yes |
No |
Do you experience Raynaud's phenomenon? |
Yes |
No |